Education
About Us
Working with TipRanks
Follow Us
4DMedical Ltd (AU:4DX)
ASX:4DX
4DX Stock Chart & Stats
AU$4.22
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$4.22
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$5.42
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.42B
Enterprise ValueAU$2.30B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta1.83
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding573,784,060
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.85Price Target Upside-8.77% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary XV Imaging Technology4DMedical's XV Technology provides differentiated, quantitative functional lung imaging not available in standard CT reads. That proprietary capability supports clinical adoption for diagnosis, treatment planning and trials, creating a durable product moat tied to clinical utility and data advantages.
Recurring, Scalable Software Business ModelThe company's mix of licensing/subscriptions and per‑scan monetisation can create recurring, scalable revenue as installed base and scan volumes grow. Service and integration revenue add customer stickiness, supporting repeatable long-term cash generation if clinical adoption expands.
Conservative Leverage And Equity BaseA low debt load gives 4DMedical financial flexibility to invest in commercialization and R&D despite current losses. Conservative leverage reduces solvency risk, preserving runway and capacity to fund sales expansion or clinical studies without immediate refinancing pressure.
Bears Say
Declining Revenue TrendA sustained revenue decline signals adoption or commercialization challenges. For a software and per‑use model, negative top-line growth undermines operating leverage and delays attainment of scale economics, extending the timeline to sustainable profitability over the medium term.
Persistent Negative Cash Flow And LossesOngoing negative operating and free cash flows alongside substantial net losses mean the company must rely on external funding to sustain operations. That constrains the ability to invest aggressively in sales or trials and raises dilution or financing risk over the coming months.
Revenue Visibility And Demand Concentration RiskLack of disclosed contract mix and dependence on scan volumes creates visibility risk: revenues may be lumpy and sensitive to hospital adoption cycles. Limited transparency on recurring contract terms increases uncertainty about predictability of medium‑term cash flows.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$5.42 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.42B.
When is 4DMedical Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 4DMedical Ltd’s earnings last quarter?
Currently, no data Available
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 573,784,060 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$3.85 (-8.77% Downside)
AU$3.85 (-8.77% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 91%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth AU$9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$3.85
▼(-8.77% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---